In a shocking development that has reignited concerns about drug safety and pharmaceutical oversight in India, the owner of a Haryana-based pharmaceutical company has been arrested following the deaths of multiple children allegedly linked to the consumption of Coldrif Syrup. The incident, which has drawn nationwide attention, underscores the urgent need for stronger quality control measures in the manufacturing and distribution of pediatric medicines.
According to official sources, the Haryana Police arrested the owner of Maiden Pharmaceuticals Ltd., the company responsible for producing the cough syrup in question, after forensic reports confirmed the presence of diethylene glycol (DEG) and ethylene glycol (EG)—toxic substances that are commonly used in industrial applications but are lethal when ingested by humans. Both compounds can cause acute kidney failure, leading to death, especially in children.
The investigation began after several fatalities were reported in Uzbekistan in late 2024, where health authorities traced the deaths of at least 19 children to the consumption of Coldrif Syrup imported from India. Subsequent laboratory tests revealed that the syrup contained toxic levels of these industrial chemicals, prompting the World Health Organization (WHO) to issue a medical product alert and advise countries to strengthen their regulatory surveillance on similar products.
Indian authorities swiftly initiated a probe, leading to the inspection of the company’s manufacturing facilities. Reports from the Central Drugs Standard Control Organisation (CDSCO) indicated severe violations of Good Manufacturing Practices (GMP), including inadequate testing, poor documentation, and lack of safety protocols. The company’s production license was suspended pending further investigation.
During a press briefing, a senior Haryana Police official confirmed the arrest, stating, “The owner was taken into custody based on concrete evidence linking the contaminated product to the deaths of children abroad. A detailed investigation is underway to identify lapses at every stage of the production and export process.” The police have also detained key quality control personnel and are working closely with the Ministry of Health to examine export documentation and supplier chains.
The tragedy has sparked widespread outrage and renewed scrutiny of India’s booming pharmaceutical export industry, which is often described as the “pharmacy of the world.” Experts argue that while the country has made significant strides in drug production, gaps in enforcement and oversight continue to allow substandard or counterfeit medicines to enter both domestic and international markets.
Public health advocates have called for stricter penalties for companies found guilty of negligence and for the establishment of an independent body to monitor pharmaceutical exports. “This is not just a regulatory failure—it’s a humanitarian disaster,” said Dr. Meera Menon, a public health policy analyst. “India’s credibility as a global drug supplier depends on the integrity of its manufacturing systems.”
As the case unfolds, the Indian government faces mounting pressure to implement systemic reforms and restore global trust in its pharmaceutical products. The arrest of the company owner marks a critical step in ensuring accountability, but experts emphasize that true reform will require sustained vigilance, transparency, and stronger legal frameworks to prevent such tragedies in the future.
